A double blind, placebo-controlled trial that combines disulfiram and naltrexone for treating co-occurring cocaine and alcohol dependence

Addictive Behaviors

Volumn 33, Issue 5, 2008, Pages 651-667

  Pettinati, Helen M ^a   Kampman, Kyle M ^a   Lynch, Kevin G ^a   Xie, Hu ^a   Dackis, Charles ^a   Rabinowitz, Amanda R ^a   OBrien, Charles P ^a,b  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Alcohol; Clinical trial; Cocaine; Combining medications; Disulfiram; Medication non adherence; Naltrexone

Indexed keywords

ALCOHOL; COCAINE; DISULFIRAM; NALTREXONE; PLACEBO;

ADULT; ALCOHOLISM; ANXIETY; ARTICLE; CLINICAL TRIAL; COCAINE DEPENDENCE; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; EVALUATION; FEMALE; HEADACHE; HUMAN; IRRITABILITY; LIBIDO DISORDER; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; NAUSEA; ORGASM DISORDER; OUTCOMES RESEARCH; PATIENT COMPLIANCE; RANDOMIZED CONTROLLED TRIAL; RASH; RECOMMENDED DRUG DOSE; SELF REPORT; SEXUAL DYSFUNCTION; SIDE EFFECT; TOOTH PAIN; UPPER RESPIRATORY TRACT INFECTION; URINALYSIS; VOMITING;

ADOLESCENT; ADULT; AGED; ALCOHOL DETERRENTS; ALCOHOLISM; COCAINE-RELATED DISORDERS; DISULFIRAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; MIDDLE AGED; NALTREXONE; NARCOTIC ANTAGONISTS; TREATMENT OUTCOME;

EID: 39849088581     PISSN: 03064603     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.addbeh.2007.11.011     Document Type: Article

References (64)

1. Ait-Daoud N., Johnson B.A., Prihoda T.J., and Hargita I.D. Combining ondansetron and naltrexone reduces craving among biologically predisposed alcoholics: Preliminary clinical evidence. Psychopharmacology 154 1 (2001) 23-27
2. Anton R.F., O'Malley S.S., Ciraulo D.A., Cisler R.A., Couper D., Donovan D.M., et al. Combined pharmacotherapies and behavioral interventions for alcohol dependence: The COMBINE study: A randomized controlled trial. Journal of the American Medical Association 295 17 (2006) 2003-2017
3. Beakeland F., Lundwall L., Kissin B., and Shanahan T. The correlates of outcome in disulfiram treatment of alcoholism. Journal of Nervous and Mental Disease 53 (1971) 1-9
4. Besson J., Aeby F., Kasas A., Lehert P., and Potgieter A. Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: A controlled study. Alcoholism: Clinical & Experimental Research 22 3 (1998) 573-579
5. Brady K.T., Sonne S., Randall C.L., Adinoff B., and Malcolm R. Features of cocaine dependence with concurrent alcohol abuse. Drug & Alcohol Dependence 39 1 (1995) 69-71
6. Carroll K., Fenton L.R., Ball S.A., Nich C., Frankforter T.L., Shi J., et al. Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients: A randomized placebo-controlled trial. Archives of General Psychiatry 61 3 (2004) 264-272
7. Carroll K., Nich C., Ball S., McCance E., Frankforter T., and Rounsaville B. One-year follow-up of disulfiram and psychotherapy for cocaine-alcohol users: Sustained effects of treatment. Addiction 95 9 (2000) 1335-1349
8. Carroll K., Nich C., Ball S., McCance E., and Rounsaville B. Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction 93 5 (1998) 713-727
9. Carroll K., Rounsaville B.J., and Bryant K.J. Alcoholism in treatment-seeking cocaine abusers: Clinical and prognostic significance. Journal of Studies on Alcohol 54 2 (1993) 199-208
10. Carroll K., Rounsaville B.J., Gordon L.T., Nich C., Jatlow P., Bisighini R.M., et al. Psychotherapy and pharmacotherapy for ambulatory cocaine abusers. Archives of General Psychiatry 51 3 (1994) 177-187
11. Dackis C., Kampman K.M., Lynch K.G., Pettinati H.M., and O′Brien C.P. A double-blind, placebo-controlled trial of modafinil for cocaine dependence. Neuropsychopharmacology 30 1 (2005) 205-211
12. Dackis C., and O′Brien C.P. Glutamatergic agents for cocaine dependence. Annals of the New York Academy of Sciences 1003 (2003) 328-345
13. De Witte P., Littleton J., Parot P., and Koob G. Neuroprotective and abstinence-promoting effects of acamprosate: Elucidating the mechanism of action. CNS Drugs 19 6 (2005) 517-537
14. First M.B., Spitzer R.L., Gibbon M., and Williams J.B. Structured Clinical Interview for DSM IV Axis I Disorders - Patient Edition (SCID-I/P, Version 2.0) (1995), New York State Psychiatric Institute, New York Biometrics Research Department
15. Flannery B.A., Morgenstern J., McKay J., Wechsberg W.M., and Litten R.Z. Co-occurring alcohol and cocaine dependence: Recent findings from clinical and field studies. Alcoholism: Clinical & Experimental Research 28 6 (2004) 976-981
16. Fuller R., and Gordis E. Does disulfiram have a role in alcoholism treatment today. Addiction 99 (2004) 21-24
17. Fuller R., Rieckmann T., McCarty D., Smith K.W., and Levine H. Adoption of naltrexone to treat alcohol dependence. Journal of Substance Abuse Treatment 28 3 (2005) 273-280
18. Gossop M., and Carroll K. Disulfiram, cocaine, and alcohol: Two outcomes for the price of one?. Alcohol & Alcoholism 41 2 (2006) 119-120
19. Gossop M., Manning V., and Ridge G. Concurrent use and order of use of cocaine and alcohol: Behavioural differences between users of crack cocaine and cocaine powder. Addiction 101 9 (2006) 1292-1298
20. Gossop M., Manning V., and Ridge G. Concurrent use of alcohol and cocaine: Differences in patterns of use and problems among users of crack cocaine and cocaine powder. Alcohol & Alcoholism 41 2 (2006) 121-125
21. Grassi M., Cioceb A., Dei Giudicib F., Antonillia L., and Nencinia P. Short-term efficacy of Disulfiram or Naltrexone in reducing positive urinalysis for both cocaine and cocaethylene in cocaine abusers: A pilot study. Pharmacological Research 55 2 (2007) 117-121
22. Hameedi F.A., Rosen M.I., McCance-Katz E.F., McMahon T.J., Price L.H., Jatlow P.I., et al. Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biological Psychiatry 37 8 (1995) 560-563
23. Hamilton M. The assessment of anxiety states by rating. British Journal of Psychiatry 32 (1959) 50-55
24. Hamilton M. A rating scale for depression. Journal of Neurology, Neurosurgery and Psychiatry 23 (1960) 56-62
25. Harris D.S., Everhart E.T., Mendelson J., and Jones R.T. The pharmacology of cocaethylene in humans following cocaine and ethanol administration. Drug & Alcohol Dependence 72 2 (2003) 169-182
26. Hearn W.L., Rose S., Wagner J., Ciarleglio A., and Mash D.C. Cocaethylene is more potent than cocaine in mediating lethality. Pharmacology, Biochemistry & Behavior 39 2 (1991) 531-533
27. Hedeker D., and Gibbons R.D. Application of random-effects pattern-mixture models for missing data in longitudinal studies. Psychological Methods 2 1 (1997) 64-78
28. Heil S.H., Badger G.J., and Higgins S.T. Alcohol dependence among cocaine-dependent outpatients: Demographics, drug use, treatment outcome and other characteristics. Journal of Studies on Alcohol 62 1 (2001) 14-22
29. Hersh D., Mulgrew C.L., Van Kirk J., and Kranzler H.R. The validity of self-reported cocaine use in two groups of cocaine abusers. Journal of Consulting & Clinical Psychology 67 1 (1999) 37-42
30. Hersh D., Van Kirk J.R., and Kranzler H.R. Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology 139 1-2 (1998) 44-52
31. Kadden R.M., Litt M.D., Cooney N.L., and Busher D.A. Relationship between role-play measures of coping skills and alcoholism treatment outcome. Addictive Behaviors 17 5 (1992) 425-437
32. Kampman K.M., Dackis C., Lynch K.G., Pettinati H.M., Tirado C., Gariti P., et al. A double-blind, placebo-controlled trial of amantadine, propranolol, and their combination for the treatment of cocaine dependence in patients with severe cocaine withdrawal symptoms. Drug & Alcohol Dependence 85 2 (2006) 129-137
33. Kampman K.M., Pettinati H.M., Lynch K.G., Dackis C., Sparkman T., Weigley C., et al. A pilot trial of topiramate for the treatment of cocaine dependence. Drug & Alcohol Dependence 75 3 (2004) 233-240
34. Kiefer F., and Wiedemann K. Combined therapy: What does acamprosate and naltrexone combination tell us?. Alcohol & Alcoholism 39 6 (2004) 542-547
35. Kosten T.R., George T.P., and Kosten T.A. The potential of dopamine agonists in drug addiction. Expert Opinion on Investigational Drugs 11 4 (2002) 491-499
36. Kosten T.R., Morgan C.M., Falcione J., and Schottenfeld R.S. Pharmacotherapy for cocaine-abusing methadone-maintained patients using amantadine or desipramine. Archives of General Psychiatry 49 11 (1992) 894-898
37. McCance-Katz E.F., Kosten T.R., and Jatlow P. Chronic disulfiram treatment effects on intranasal cocaine administration: Initial results. Biological Psychiatry 43 7 (1998) 540-543
38. McCance-Katz E.F., Kosten T.R., and Jatlow P. Disulfiram effects on acute cocaine administration. Drug & Alcohol Dependence 52 1 (1998) 27-39
39. Mengis M.M., Maude-Griffin P.M., Delucchi K., and Hall S.M. Alcohol use affects the outcome of treatment for cocaine abuse. American Journal on Addictions 11 3 (2002) 219-227
40. Nich C., McCance-Katz E., Petrakis I., Cubellsa J., Rounsaville B., and Carroll K. Sex differences in cocaine-dependent individuals′ response to disulfiram treatment. Addictive Behaviors 29 6 (2004) 1123-1128
41. O ́Malley S.S., Jaffe A.J., Chang G., Schottenfeld R.S., Meyer R.E., and Rounsaville B. Naltrexone and coping skills therapy for alcohol dependence. A controlled study. Archives of General Psychiatry 49 11 (1992) 881-887
42. Oslin D.W., Pettinati H.M., Volpicelli J.R., Wolf A.L., Kampman K.M., and O′Brien C.P. The effects of naltrexone on alcohol and cocaine use in dually addicted patients. Journal of Substance Abuse Treatment 16 2 (1999) 163-167
43. Paille F.M., Guelfi J.D., Perkins A.C., Royer R.J., Steru L., and Parot. Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol 30 2 (1995) 239-247
44. Park T., and Lee S.Y. Simple pattern-mixture models for longitudinal data with missing observations: Analysis of urinary incontinence data. Statistics in Medicine 18 21 (1999) 2933-2941
45. Pelc I., Verbanck P., Le Bon O., Gavrilovic M., Lion K., and Lehert P. Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. British Journal of Psychiatry 171 (1997) 73-77
46. Pennings E.J.M., Leccese A.P., and Wolff F.A. Effects of concurrent use of alcohol and cocaine. Addiction 97 7 (2002) 773-783
47. Petrakis I., Carroll K., Nich C., Gordon L., McCance-Katz E., Frankforter T., et al. Disulfiram treatment for cocaine dependence in methadone-maintained opioid addicts. Addiction 95 2 (2000) 219-228
48. Petrakis I., Poling J., Levinson C., Nich C., Carroll K., Rounsaville B., et al. Naltrexone and disulfiram in patients with alcohol dependence and comorbid psychiatric disorders. Biological Psychiatry 57 10 (2005) 1128-1137
49. Pettinati, H. M., Kampman, K. M., Lynch, K. G., Suh, J. J., Dackis, C., Oslin, D. W., et al. (in press). Gender Differences with High Dose Naltrexone in Cocaine and Alcohol Dependent Patients. Journal of Substance Abuse Treatment. doi:10.1016/j.jsat.2007.05.011.
50. Pettinati H.M., O′Brien C.P., Rabinowitz A.R., Wortman S.P., Oslin D.W., Kampman K.M., et al. The status of naltrexone in the treatment of alcohol dependence: Specific effects on heavy drinking. Journal of Clinical Psychopharmacology 26 6 (2006) 610-625
51. Rabkin J.G., Markowitz J.S., Ocepek-Welikson K., and Wager S.S. General versus systematic inquiry about emergent clinical events with SAFTEE: Implications for clinical research. Journal of Clinical Psychopharmacology 12 (1992) 3-10
52. Sass H., Soyka M., Mann K., and Zieglgansberger W. Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Archives of General Psychiatry 53 8 (1996) 673-680
53. Schmitz J.M., Stotts A.L., Sayre S.L., DeLaune K.A., and Grabowski J. Treatment of cocaine-alcohol dependence with naltrexone and relapse prevention therapy. American Journal on Addictions 13 4 (2004) 333-341
54. Sharples K., and Breslow N. Regression analysis of correlated binary data: Some small sample results for the estimating equation approach. Journal of Statistical Computation and Simulation 42 (1992) 1-20
55. Shoptaw S., Kintaudi P.C., Charuvastra C., and Ling W. A screening trial of amantadine as a medication for cocaine dependence. Drug & Alcohol Dependence 66 3 (2002) 217-224
56. Sobell L.C., and Sobell M.B. Timeline follow-back: A technique for assessing self-reported alcohol consumption. In: Allen J. (Ed). Measuring Alcohol Consumption (1992), Humana Press Inc, Totowa, NJ 41-65
57. Sofuoglu M., Singha A., Kosten T.R., McCance-Katz F.E., Petrakis I., and Oliveto A. Effects of naltrexone and isradipine, alone or in combination, on cocaine responses in humans. Pharmacology Biochemistry and Behavior 75 4 (2003) 801-808
58. Suh J.J., Pettinati H.M., Kampman K.M., and O′Brien C.P. The status of disulfiram: A half of a century later. Journal of Clinical Psychopharmacology 26 3 (2006) 290-302
59. Vocci F.J., Acri J., and Elkashef A. Medication development for addictive disorders: The state of the science. American Journal of Psychiatry 162 8 (2005) 1432-1440
60. Volpicelli J.R., O′Brien C.P., Alterman A.I., and Hayashida M. Naltrexone and the treatment of alcohol dependence: Initial observations. In: Reid L.D. (Ed). Opiods, Bulimia, and Alcohol Abuse & Alcoholism (1990), Springer-Verlag, New York, NY 195-214
61. Volpicelli J.R., Rhines K.C., Rhines J.S., Volpicelli L.A., Alterman A.I., and O′Brien C.P. Naltrexone and alcohol dependence. Role of subject compliance. Archives of General Psychiatry 54 8 (1997) 737-742
62. Volpicelli J.R., Watson N.T., King A.C., Sherman C.E., and O′Brien C.P. Effect of naltrexone on alcohol "high" in alcoholics. American Journal of Psychiatry 152 4 (1995) 613-615
63. Walsh S.L., Sullivan J.T., Preston K.L., Garner J.E., and Bigelow G.E. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans. The Journal of Pharmacology and Experimental Therapeutics 279 2 (1996) 524-538
64. Zanis D.A., McLellan A.T., and Randall M. Can you trust patient self-reports of drug use during treatment?. Drug & Alcohol Dependence 35 2 (1994) 127-132